Advances in Therapeutic Applications of Fish Oil, 2nd Edition

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine-Derived Ingredients for Drugs, Cosmeceuticals and Nutraceuticals".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 413

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pharmacological and Biomolecular Sciences “Rodolfo Paoletti”, University of Milan, Milan, Italy
Interests: lipoproteins; marine fish proteins; fish oil; functional foods; atherosclerosis; animal models
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The World Health Organization estimates that cardiovascular disease (CVD) remains the number one cause of death worldwide, and the residual risk after implementing all current therapies is still high. It is thus crucial that all health professionals make appropriate use of all the available intervention strategies to control risk factors. Although genetic factors and aging are important in determining the overall risk, a substantial proportion of CVD occurs in conjunction with a series of modifiable risk factors, such as hyperlipidemia, hypertension, obesity, insulin resistance and diabetes, susceptible to lifestyle modifications, which include dietary improvement, adequate physical activity and the use of functional foods, food supplements and drugs. Emerging research has explored the application of natural food-based strategies in disease management. With marine species comprising approximately half of the global biodiversity, the ocean offers a wonderful resource for novel compounds, which may serve to improve the health of the worldwide population. Many of the positive effects of fish, including those on dyslipidemia and heart disease, have been attributed to fish oil, and more specifically to n-3 PUFAs, i.e., EPA and DHA.

As with the first edition that was closed in 2021 (https://www.mdpi.com/journal/marinedrugs/special_issues/fish_oil), the aim of this Special Issue is to gather new information regarding the novel therapeutic applications of fish oil. In addition, this research topic intends to update information about the use of fish oil in CVD and other human diseases.

Dr. Cinzia Parolini
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • EPA
  • DHA
  • N-3 PUFA
  • marine-derived ingredients
  • nutraceutical
  • triglycerides
  • cardiovascular diseases
  • obesity
  • insulin resistance
  • metabolic syndrome

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 8423 KiB  
Article
Predigested Mixture of Arachidonic and Docosahexaenoic Acids for Better Bio-Accessibility
by Assamae Chabni, Blanca Pardo de Donlebún, Marina Romero and Carlos F. Torres
Mar. Drugs 2024, 22(5), 224; https://doi.org/10.3390/md22050224 - 16 May 2024
Viewed by 180
Abstract
A predigested product from arachidonic acid oil (ARA) and docosahexaenoic acid (DHA) oil in a 2:1 (w/w) ratio has been developed and evaluated in an in vitro digestion model. To produce this predigested lipid mixture, first, the two oils [...] Read more.
A predigested product from arachidonic acid oil (ARA) and docosahexaenoic acid (DHA) oil in a 2:1 (w/w) ratio has been developed and evaluated in an in vitro digestion model. To produce this predigested lipid mixture, first, the two oils were enzymatically hydrolyzed up to 90% of free fatty acids (FFAs) were achieved. Then, these two fatty acid (FA) mixtures were mixed in a 2:1 ARA-to-DHA ratio (w/w) and enzymatically esterified with glycerol to produce a mixture of FFAs, mono-, di-, and triacylglycerides. Different glycerol ratios and temperatures were evaluated. The best results were attained at 10 °C and a glycerol-to-FA molar ratio of 3:1. The bio-accessibility of this predigested mixture was studied in an in vitro digestion model. A total of 90% of the digestion product was found in the micellar phase, which contained 30% monoacylglycerides, more than 50% FFAs, and a very small amount of triacylglycerols (3% w/w). All these data indicate an excellent bio-accessibility of this predigested mixture. Full article
(This article belongs to the Special Issue Advances in Therapeutic Applications of Fish Oil, 2nd Edition)
Show Figures

Graphical abstract

Back to TopTop